As­traZeneca inks deal with Japan­ese biotech JCR in CNS in­di­ca­tion

As­traZeneca and its rare dis­ease unit Alex­ion are do­ing a deal with JCR Phar­ma­ceu­ti­cals, which will see them use JCR’s tech­nol­o­gy to try to de­vel­op a drug that can cross the blood-brain bar­ri­er for an undis­closed neu­rode­gen­er­a­tive dis­ease.

The deal, of­fi­cial­ly an­nounced Mon­day morn­ing, did not dis­close any fi­nan­cial specifics. How­ev­er, the com­pa­nies con­firmed that JCR gets an up­front pay­ment, plus mile­stones and roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER